La Jolla Pharmaceutical (LJPC) announced Monday morning that its Phase 3 study of LJPC-501 in patients with catecholamine resistant hypotension was highly statistically significant in terms of its primary endpoint. Only 23% of the 158 placebo-treated patients had a blood pressure response compared to 70% of the 163 LJPC-501-treated patients.
La Jolla Pharmaceutical has gapped open sharply higher Monday morning and is now up 10.01 at $29.88 on the highest volume of the year. The stock has surged past resistance and has set a new high for the year.
by RTT Staff Writer
For comments and feedback: email@example.com